These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19577347)

  • 1. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
    Levey AS; Cattran D; Friedman A; Miller WG; Sedor J; Tuttle K; Kasiske B; Hostetter T
    Am J Kidney Dis; 2009 Aug; 54(2):205-26. PubMed ID: 19577347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
    Levey AS; Gansevoort RT; Coresh J; Inker LA; Heerspink HL; Grams ME; Greene T; Tighiouart H; Matsushita K; Ballew SH; Sang Y; Vonesh E; Ying J; Manley T; de Zeeuw D; Eckardt KU; Levin A; Perkovic V; Zhang L; Willis K
    Am J Kidney Dis; 2020 Jan; 75(1):84-104. PubMed ID: 31473020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
    Levey AS; Inker LA; Matsushita K; Greene T; Willis K; Lewis E; de Zeeuw D; Cheung AK; Coresh J
    Am J Kidney Dis; 2014 Dec; 64(6):821-35. PubMed ID: 25441437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).
    Eknoyan G; Hostetter T; Bakris GL; Hebert L; Levey AS; Parving HH; Steffes MW; Toto R
    Am J Kidney Dis; 2003 Oct; 42(4):617-22. PubMed ID: 14520612
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration.
    Inker LA; Grams ME; Guðmundsdóttir H; McEwan P; Friedman R; Thompson A; Weiner DE; Willis K; Heerspink HJL;
    Am J Kidney Dis; 2022 Oct; 80(4):513-526. PubMed ID: 35970679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug Administration.
    Perrone RD; Coons SJ; Cavanaugh K; Finkelstein F; Meyer KB
    Am J Kidney Dis; 2013 Dec; 62(6):1046-57. PubMed ID: 23988757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.
    Stoycheff N; Pandya K; Okparavero A; Schiff A; Levey AS; Greene T; Stevens LA
    Nephrol Dial Transplant; 2011 Mar; 26(3):848-57. PubMed ID: 20817671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease.
    Montañés Bermúdez R; Gràcia García S; Pérez Surribas D; Martínez Castelao A; Bover Sanjuán J; ;
    Nefrologia; 2011; 31(3):331-45. PubMed ID: 21780317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.
    Heerspink HJL; Greene T; Tighiouart H; Gansevoort RT; Coresh J; Simon AL; Chan TM; Hou FF; Lewis JB; Locatelli F; Praga M; Schena FP; Levey AS; Inker LA;
    Lancet Diabetes Endocrinol; 2019 Feb; 7(2):128-139. PubMed ID: 30635226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.
    Agarwal R
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1523-8. PubMed ID: 19478099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing for chronic kidney disease: a position statement from the National Kidney Foundation.
    Vassalotti JA; Stevens LA; Levey AS
    Am J Kidney Dis; 2007 Aug; 50(2):169-80. PubMed ID: 17660017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early diagnosis of chronic kidney disease. New insights into creatinine and proteinuria].
    Brandenburg V; Floege J
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():158-62. PubMed ID: 16802544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.
    Thompson A; Cattran DC; Blank M; Nachman PH
    J Am Soc Nephrol; 2015 Dec; 26(12):2930-7. PubMed ID: 26078365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE).
    Hogg RJ; Portman RJ; Milliner D; Lemley KV; Eddy A; Ingelfinger J
    Pediatrics; 2000 Jun; 105(6):1242-9. PubMed ID: 10835064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Wish JB; Charytan C; Chertow GM; Kalantar-Zadeh K; Kliger AS; Rubin RJ; Yee J; Fishbane S
    Am J Kidney Dis; 2016 Dec; 68(6):843-852. PubMed ID: 27599628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria versus albuminuria in chronic kidney disease.
    Guh JY
    Nephrology (Carlton); 2010 Jun; 15 Suppl 2():53-6. PubMed ID: 20586950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US Food and Drug Administration Recommendations on the Use of Surrogate Measures as End Points in New Anti-infective Drug Approvals.
    Hey SP; Kesselheim AS; Patel P; Mehrotra P; Powers JH
    JAMA Intern Med; 2020 Jan; 180(1):131-138. PubMed ID: 31710344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should proteinuria be detected and measured?
    Lamb EJ; MacKenzie F; Stevens PE
    Ann Clin Biochem; 2009 May; 46(Pt 3):205-17. PubMed ID: 19389884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of proteinuria and glomerular filtration rate on Taiwanese patients with diabetes mellitus and advanced chronic kidney disease: a single center experience.
    Chen PM; Wada T; Chiang CK
    Clin Exp Nephrol; 2017 Apr; 21(2):307-315. PubMed ID: 27339442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.